Novo Ventures

Investor type Corporate Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 76
Average round size
info
The average size of a deal this fund participated in
$33M
Portfolio companies 58
Rounds per year 3.30
Lead investments 22
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.24
Exits 36
Key employees 7

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

The main department of described VC is located in the Bagsvu00e6rd. The company was established in Europe in Denmark. Novo Ventures appeared to be a CVC structure as part of the corporation.

Among the most popular portfolio startups of the fund, we may highlight Spectranetics, Alios BioPharma, Cianna Medical. The fund has exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Genetics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Novo Ventures, startups are often financed by Novartis Venture Fund, Novo Holdings, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are TPG Biotech, New Enterprise Associates, Versant Ventures. In the next rounds fund is usually obtained by Novo Holdings, SV Health Investors, TPG Biotech.

Besides them, we counted 7 critical employees of this fund in our database.

The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Novo Ventures performs on 16 percentage points more the average number of lead investments. Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year. The increased amount of exits for fund were in 2014. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Novo Ventures:
Typical Co-investors
Novo Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Novo Ventures:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Bandai Namco Entertainment Chiyoda, Japan
Century Financial Partners -
Chun Yang Investment Management China, Shanghai
Dundee Goodman Merchant Partners Canada, Ontario, Toronto
Everbright Prestige Capital Beijing, Beijing, China
ProQuest Investments New Jersey, Princeton, United States
Suffolk Capital -
Thunder Bay Ventures Canada, Ontario, Thunder Bay

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Amolyt Pharma

Health Care
Medical
Therapeutics
$80M16 Sep 2021 Écully, Rhone-Alpes, France

INBRACE

Consumer
Dental
Health Care
Medical Device
Wellness
$102M08 Sep 2021 Irvine, California, United States

Reneo Pharmaceuticals

Biotechnology
Medical
Pharmaceutical
$95M09 Dec 2020 San Diego, California, United States

Lava Therapeutics

Biotechnology
Life Science
Medical
Medical Device
$83M17 Sep 2020 Utrecht, Utrecht, Netherlands

F2G

Biotechnology
Genetics
Health Care
Medical
Pharmaceutical
$60M12 Aug 2020 Manchester, England, United Kingdom

NodThera

Biotechnology
Health Care
Life Science
$55M03 Jun 2020 Uttlesford, England, United Kingdom

Anokion

Biotechnology
Clinical Trials
Therapeutics
$40M11 Sep 2019 Vaud, Switzerland

Amolyt Pharma

Health Care
Medical
Therapeutics
$79M31 Jul 2019 Écully, Rhone-Alpes, France

Galera Therapeutics

Biotechnology
Life Science
Therapeutics
$70M19 Sep 2018 Pennsylvania, United States
News
Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Novo Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: